MARKET

OTLC

OTLC

Oncotelic Therapeutics Inc
OTCMQB

Real-time Quotes | Nasdaq Last Sale

0.195
0.000
0.00%
Opening 10:03 05/16 EDT
OPEN
0.195
PREV CLOSE
0.195
HIGH
0.195
LOW
0.195
VOLUME
5.00K
TURNOVER
975
52 WEEK HIGH
0.338
52 WEEK LOW
0.081
MARKET CAP
72.70M
P/E (TTM)
-2.4074
1D
5D
1M
3M
1Y
5Y
ONCOTELIC ANNOUNCES US PATENT GRANT FOR CA4P AND OXI4503 COMBINATION WITH CHECKPOINT INHIBITORS
AGOURA HILLS, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), is pleased to announce the grant of patent application no. 15/753,882 entitled “USE OF VDAS TO ENHANCE IMMUNOMODULATING THERAPI...
GlobeNewswire · 5d ago
Oncotelic Appoints Seymour Fein M.D. as Chief Regulatory Officer
AGOURA HILLS, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), today announced the appointment of Dr. Seymour Fein as its Chief Regulatory Officer. Dr. Fein will guide the company registrati...
GlobeNewswire · 05/04 11:00
BRIEF-Oncotelic Appoints Fatih Uckun As Chief Medical Officer
reuters.com · 05/03 12:29
Oncotelic Appoints Fatih Uckun, M.D., Ph.D., as Chief Medical Officer
AGOURA HILLS, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company” or “We”) (OTCQB:OTLC), today announced the appointment of Dr. Fatih Uckun as its Chief Medical Officer. Dr. Uckun will be responsible for exec...
GlobeNewswire · 05/03 11:00
ONCOTELIC PROVIDES YE 2021 FINANCIAL RESULTS COMPARED TO YE 2020, PRODUCT DEVELOPMET INITIATIVES AND CORPORATE UPDATE
AGOURA HILLS, Calif., April 18, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic”, “We” or the “Company”) (OTCQB:OTLC) today announced financial results for the full year ended December 31, 2021 (“FY 2021”) as compared to the full year end...
GlobeNewswire · 04/18 11:00
Letter to Oncotelic Shareholders on the Recently Completed Joint Venture Transaction with Dragon Overseas Capital Limited
AGOURA HILLS, Calif., April 07, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), issued the following shareholder letter today. Dear Fellow Shareholders, We would like to thank you for being part of our mis...
GlobeNewswire · 04/07 14:00
Oncotelic and Dragon Overseas Capital Limited Completed Joint Venture Transaction
AGOURA HILLS, Calif., April 04, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), today announced the formation of a Joint Venture (“JV”) with Dragon Overseas Capital Limited (“Dragon Overseas”). Dragon Over...
GlobeNewswire · 04/04 11:00
Oncotelic to Present New Studies on its TGF-β Program at the American Association for Cancer Research (AACR) Annual Meeting 2022
●OT-101 is Oncotelic’s RNA Therapeutic Against TGF-β●OT-101 has completed over six clinical trials against solid tumors with good efficacy●OT-101 is currently undergoing a phase 1b trial in combination with IL-2●Multiple trials combining OT-101 with pembro...
GlobeNewswire · 03/10 13:05
More
No Data
Learn about the latest financial forecast of OTLC. Analyze the recent business situations of Oncotelic Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average OTLC stock price target is 4.000 with a high estimate of 4.000 and a low estimate of 4.000.
High4.000
Average4.000
Low4.000
Current 0.1950
EPS
Actual
Estimate
-0.03-0.02-0.02-0.01
Q4 2020
Q1 2021
Q2 2021
    0
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 0
Institutional Holdings: 0
% Owned: 0.00%
Shares Outstanding: 372.81M
TypeInstitutionsShares
Increased
0
0
New
0
0
Decreased
0
0
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.65%
Pharmaceuticals & Medical Research
+0.99%
Key Executives
Chief Executive Officer
Vuong Trieu
Chief Financial Officer
Amit Shah
Other
Seymour Fein
Director
Steven King
Director
Anthony Maida
No Data
No Data
About OTLC
Oncotelic Therapeutics, Inc., formerly Mateon Therapeutics, Inc., is an immuno-oncology company. The Company is engaged in development of ribonucleic acid (RNA) therapeutics as well as small molecule drugs against cancer and infectious diseases. The Company’s pipeline includes ArtiVeda/ArtiShield, OT-101, CA4P and Oxi4503. The ArtiVeda/ArtiShield is a derivative from the plant Artemisia. Its immuno-oncology drug candidate, OT-101, is developed for the treatment of solid tumors with focus on brain cancer in adult and diffuse intrinsic pontine glioma (DIPG) in children. The Company’s OT-101 completed phase II for pancreatic cancer, melanoma, and glioblastoma. Its CA4P is a vascular disrupting agent (VDA) in combination with Ipilimumab for the treatment of solid tumors with focus on melanoma in adult and pediatric melanoma. The OXi4503 is developed for the treatment of liquid tumors with focus on childhood leukemia.

Webull offers kinds of Oncotelic Therapeutics Inc stock information, including OTCMQB:OTLC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OTLC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading OTLC stock methods without spending real money on the virtual paper trading platform.